MX9701327A - Methods of inhibiting endometrial cancer. - Google Patents

Methods of inhibiting endometrial cancer.

Info

Publication number
MX9701327A
MX9701327A MX9701327A MX9701327A MX9701327A MX 9701327 A MX9701327 A MX 9701327A MX 9701327 A MX9701327 A MX 9701327A MX 9701327 A MX9701327 A MX 9701327A MX 9701327 A MX9701327 A MX 9701327A
Authority
MX
Mexico
Prior art keywords
endometrial cancer
methods
inhibiting endometrial
inhibiting
hexamethyleneimino
Prior art date
Application number
MX9701327A
Other languages
Spanish (es)
Inventor
Susan Margaret Boss
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9701327A publication Critical patent/MX9701327A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

A method of inhibiting endometrial cancer comprising administering to a human in need thereof an effective amount of a compound having formula (I) wherein R1 and R3 are independently hydrogen, -CH3, (a), or (b), wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
MX9701327A 1994-08-22 1995-08-21 Methods of inhibiting endometrial cancer. MX9701327A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29385394A 1994-08-22 1994-08-22
PCT/US1995/010651 WO1996005833A1 (en) 1994-08-22 1995-08-21 Methods of inhibiting endometrial cancer

Publications (1)

Publication Number Publication Date
MX9701327A true MX9701327A (en) 1997-05-31

Family

ID=23130867

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701327A MX9701327A (en) 1994-08-22 1995-08-21 Methods of inhibiting endometrial cancer.

Country Status (17)

Country Link
EP (1) EP0777476A4 (en)
JP (1) JPH10504824A (en)
KR (1) KR970705387A (en)
AU (1) AU688112B2 (en)
CA (1) CA2198119A1 (en)
CZ (1) CZ51897A3 (en)
FI (1) FI970717A (en)
HU (1) HUT76890A (en)
IL (1) IL115022A (en)
MX (1) MX9701327A (en)
MY (1) MY113757A (en)
NO (1) NO970783L (en)
NZ (1) NZ292017A (en)
RU (1) RU2161964C2 (en)
TW (1) TW404834B (en)
WO (1) WO1996005833A1 (en)
ZA (1) ZA956994B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
KR20160066490A (en) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 Heterocyclic derivatives and use thereof
CN115825414B (en) * 2023-01-09 2023-04-25 中国医学科学院北京协和医院 Blood or urine metabolic marker and application thereof in endometrial cancer early screening

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
JP3157882B2 (en) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 New benzothiophene derivatives
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
JPH08512197A (en) * 1993-04-07 1996-12-24 リガンド・ファーマシューティカルズ・インコーポレーテッド Method for screening receptor agonist
IL111287A0 (en) * 1993-10-15 1994-12-29 Lilly Co Eli Methods for treating resistant neoplasms
WO1996005832A1 (en) * 1994-08-22 1996-02-29 Eli Lilly And Company Methods of inhibiting primary endometrial hyperplasia
US5843964A (en) * 1994-09-22 1998-12-01 Eli Lilly And Company Methods of inhibiting endometrial mitoses

Also Published As

Publication number Publication date
AU688112B2 (en) 1998-03-05
IL115022A (en) 2000-07-31
FI970717A0 (en) 1997-02-20
AU3370095A (en) 1996-03-14
NO970783D0 (en) 1997-02-20
MY113757A (en) 2002-05-31
CA2198119A1 (en) 1996-02-29
TW404834B (en) 2000-09-11
JPH10504824A (en) 1998-05-12
ZA956994B (en) 1997-02-21
WO1996005833A1 (en) 1996-02-29
NO970783L (en) 1997-02-20
EP0777476A1 (en) 1997-06-11
KR970705387A (en) 1997-10-09
HUT76890A (en) 1997-12-29
EP0777476A4 (en) 1999-06-23
FI970717A (en) 1997-02-20
RU2161964C2 (en) 2001-01-20
NZ292017A (en) 2000-07-28
CZ51897A3 (en) 1997-06-11
IL115022A0 (en) 1998-06-15

Similar Documents

Publication Publication Date Title
MX9701329A (en) Methods of inhibiting viral replication.
MX9701325A (en) Methods of inhibiting ulcerative mucositis.
AU7578794A (en) Methods for inhibiting endometriosis
MX9701360A (en) Methods of inhibiting demyelinating and dysmyelinating diseases.
MX9701334A (en) Methods for inhibiting bone prosthesis degeneration.
MX9709466A (en) Methods of inhibiting melanoma.
MX9701327A (en) Methods of inhibiting endometrial cancer.
MX9702148A (en) Methods of inhibiting endometrial mitoses.
MX9701333A (en) Methods for inhibiting neuronal damage.
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
MX9701332A (en) Methods for bone healing and fracture repair.
MX9701359A (en) Methods of inhibiting primary endometrial hyperplasia.
MX9701331A (en) Methods of maintaining teeth and oral bone.
MX9701328A (en) Methods of reducing scarring in wound healing.
MX9705940A (en) Methods of inhibiting effects of il-6
MX9706520A (en) Methods of inhibiting ovarian cancer.
MX9706072A (en) Methods of inhibiting cell-cell adhesion.
MX9709536A (en) Methods of inducing bef-1 transcription factor.
MX9705215A (en) Methods of inhibiting growth hormone effects.
MX9806036A (en) Methods of inhibiting colon tumors.
MX9705537A (en) Methods of inhibiting environmental estrogens.
MX9709651A (en) METHODS OF MODULATING NF-kB TRANSCRIPTION FACTOR.
MX9705697A (en) Methods of decreasing serum calcium levels.
MX9702853A (en) Methods of inhibiting conditions associated with neuropeptide y.